The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Open accessAbstract
Background: The biological processes associated with postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods: We measured soluble markers of inflammation in a SARS-CoV-2 recovery cohort at early (<90 days) and late (>90 days) timepoints. We defined PASC as the presence of 1 or more coronavirus disease 2019 (COVID-19)–attributed symptoms beyond 90 days. We compared fold-changes in marker values between those with and without PASC using mixed-effects models with terms for PASC and early and late recovery time periods. Results: During early recovery, those who went on to develop PASC generally had higher levels of cytokine biomarkers including tumor necrosis factor–α (1.14-fold higher mean ratio [95% confidence interval {CI}, 1.01–1.28]; P = .028) and interferon-γ–induced protein 10 (1.28-fold higher mean ratio [95% CI, 1.01–1.62]; P = .038). Among those with PASC, there was a trend toward higher interleukin 6 levels during early recovery (1.29-fold higher mean ratio [95% CI, .98–1.70]; P = .07), which became more pronounced in late recovery (1.44-fold higher mean ratio [95% CI, 1.11–1.86]; P < .001). These differences were more pronounced among those with a greater number of PASC symptoms. Conclusions: Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing PASC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200203000-00008 · Cited by 3,298
Attributes and predictors of long COVID
Sudre, C. H., Murray, B., Varsavsky, T., Graham, M. S., Penfold, R. S., Bowyer, R. C., Pujol, J. C., Klaser, K., Antonelli, M., Canas, L. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01292-y · Cited by 2,707
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Self-citationInterleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
High-dimensional characterization of post-acute sequelae of COVID-19
Al-Aly, Z., Xie, Y., & Bowe, B. (2021) · Nature · doi:10.1038/s41586-021-03553-9 · Cited by 1,518
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,291
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Han, H., Ma, Q., Li, C., Liu, R., Zhao, L., Wang, W., Zhang, P., Liu, X., Gao, G., Liu, F., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1770129 · Cited by 1,148
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
RECOVERY Collaborative Group (2021) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · doi:10.17863/cam.70428 · Cited by 1,067
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.
Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D., Oldstone, M. B., & Mucke, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10061 · Cited by 1,006
A dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
New-onset diabetes in Covid-19
Rubino, F., Amiel, S. A., Zimmet, P., Alberti, G., Bornstein, S., Eckel, R. H., Mingrone, G., Boehm, B., Cooper, M. E., Chai, Z., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2018688 · Cited by 801
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 684
Long COVID in a prospective cohort of home-isolated patients
Blomberg, B., Mohn, K. G.-I., Brokstad, K. A., Zhou, F., Linchausen, D. W., Hansen, B.-A., Lartey, S., Onyango, T. B., Kuwelker, K., Sævik, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01433-3 · Cited by 659
Interleukin-6 Overexpression Induces Pulmonary Hypertension
Steiner, M. K., Syrkina, O. L., Kolliputi, N., Mark, E. J., Hales, C. A., & Waxman, A. B. (2009) · Circulation Research · doi:10.1161/circresaha.108.182014 · Cited by 655
Fong, Y., Tracey, K. J., Moldawer, L. L., Hesse, D. G., Manogue, K. B., Kenney, J. S., Lee, A. T., Kuo, G. C., Allison, A. C., & Lowry, S. F. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1627 · Cited by 641
Serrano-Villar, S., Sainz, T., Lee, S. A., Hunt, P. W., Sinclair, E., Shacklett, B. L., Ferre, A. L., Hayes, T. L., Somsouk, M., Hsue, P. Y., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004078 · Cited by 611
Self-citationIgG1 plasmacytosis in interleukin 6 transgenic mice
Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., & Kishimoto, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7547 · Cited by 586
Tenorio, A. R., Zheng, Y., Bosch, R. J., Krishnan, S., Rodriguez, B., Hunt, P. W., Plants, J., Seth, A., Wilson, C. C., Deeks, S. G., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu254 · Cited by 546
Self-citationNew-onset IgG autoantibodies in hospitalized patients with COVID-19
Chang, S. E., Feng, A., Meng, W., Apostolidis, S. A., Mack, E., Artandi, M., Barman, L., Bennett, K., Chakraborty, S., Chang, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25509-3 · Cited by 489
Hunt, P. W., Sinclair, E., Rodriguez, B., Shive, C., Clagett, B., Funderburg, N., Robinson, J., Huang, Y., Epling, L., Martin, J. N., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu238 · Cited by 478
Self-citationSubacute Thyroiditis After Sars-COV-2 Infection
Brancatella, A., Ricci, D., Viola, N., Sgrò, D., Santini, F., & Latrofa, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa276 · Cited by 370
Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
Chen, X., Pan, Z., Yue, S., Yu, F., Zhang, J., Yang, Y., Li, R., Liu, B., Yang, X., Gao, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00301-9 · Cited by 238
Thwaites, R. S., Sanchez Sevilla Uruchurtu, A., Siggins, M. K., Liew, F., Russell, C. D., Moore, S. C., Fairfield, C., Carter, E., Abrams, S., Short, C.-E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg9873 · Cited by 234
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
Galván-Román, J. M., Rodríguez-García, S. C., Roy-Vallejo, E., Marcos-Jiménez, A., Sánchez-Alonso, S., Fernández-Díaz, C., Alcaraz-Serna, A., Mateu-Albero, T., Rodríguez-Cortes, P., Sánchez-Cerrillo, I., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.018 · Cited by 220
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
Chen, Y., Zuiani, A., Fischinger, S., Mullur, J., Atyeo, C., Travers, M., Lelis, F. J. N., Pullen, K. M., Martin, H., Tong, P., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.051 · Cited by 186
C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19
Sharifpour, M., Rangaraju, S., Liu, M., Alabyad, D., Nahab, F. B., Creel-Bulos, C., & Jabaley, C. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242400 · Cited by 163
Peluso, M. J., Kelly, J. D., Lu, S., Goldberg, S. A., Davidson, M. C., Mathur, S., Durstenfeld, M. S., Spinelli, M. A., Hoh, R., Tai, V., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab640 · Cited by 131
Self-citationSARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh3409 · Cited by 130
Self-citationAntibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections
Lei, Q., Li, Y., Hou, H., Wang, F., Ouyang, Z., Zhang, Y., Lai, D., Ndzouboukou, J. B., Xu, Z., Zhang, B., et al. (2020) · Allergy · doi:10.1111/all.14622 · Cited by 126
Ong, S. W. X., Fong, S., Young, B. E., Chan, Y., Lee, B. T. K., Amrun, S. N., Chee, R. S., Yeo, N. K., Tambyah, P. A., Pada, S., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab156 · Cited by 124
Tumor necrosis factor-α confers cardioprotection through ectopic expression of keratins K8 and K18
Papathanasiou, S., Rickelt, S., Soriano, M. E., Schips, T. G., Maier, H. J., Davos, C. H., Varela, A., Kaklamanis, L., Mann, D. L., & Capetanaki, Y. (2015) · Nature Medicine · doi:10.1038/nm.3925 · Cited by 117
Lavillegrand, J., Garnier, M., Spaeth, A., Mario, N., Hariri, G., Pilon, A., Berti, E., Fieux, F., Thietart, S., Urbina, T., et al. (2021) · Annals of Intensive Care · doi:10.1186/s13613-020-00798-x · Cited by 105
Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019
Kowitdamrong, E., Puthanakit, T., Jantarabenjakul, W., Prompetchara, E., Suchartlikitwong, P., Putcharoen, O., & Hirankarn, N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240502 · Cited by 81
Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
Bonny, T. S., Patel, E. U., Zhu, X., Bloch, E. M., Grabowski, M. K., Abraham, A. G., Littlefield, K. E., Shrestha, R., Benner, S. E., Laeyendecker, O. B., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa574 · Cited by 52
Naaber, P., Hunt, K., Pesukova, J., Haljasmägi, L., Rumm, A. P., Peterson, P., Hololejenko, J., Eero, I., Jõgi, P., Toompere, K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237548 · Cited by 51
Chen, Q., Yu, B., Yang, Y., Huang, J., Liang, Y., Zhou, J., Li, L., Peng, X., Cheng, B., & Lin, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107685 · Cited by 30
Bhadelia, N., Belkina, A. C., Olson, A., Winters, T., Urick, P., Lin, N., Rifkin, I. R., Kataria, Y., Yuen, R. R., Sagar, M., et al. (2021) · medRxiv · doi:10.1101/2021.01.21.21249176 · Cited by 25
Cited by
Long COVID: major findings, mechanisms and recommendations
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00846-2 · Cited by 4,153
The immunology and immunopathology of COVID-19
Merad, M., Blish, C. A., Sallusto, F., & Iwasaki, A. (2022) · Science · doi:10.1126/science.abm8108 · Cited by 751
Swank, Z., Senussi, Y., Manickas-Hill, Z., Yu, X. G., Li, J. Z., Alter, G., & Walt, D. R. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac722 · Cited by 572
The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19
Schultheiß, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Henkes, S.-S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100663 · Cited by 431
Yin, K., Peluso, M. J., Luo, X., Thomas, R., Shin, M.-G., Neidleman, J., Andrew, A., Young, K. C., Ma, T., Hoh, R., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01724-6 · Cited by 394
Self-citation
Metadata
- Authors
- Peluso, M. J., Lu, S., Tang, A. F., Durstenfeld, M. S., Ho, H.-E., Goldberg, S. A., Forman, C. A., Munter, S. E., Hoh, R., Tai, V., Chenna, A., Yee, B. C., Winslow, J. W., Petropoulos, C. J., Greenhouse, B., Hunt, P. W., Hsue, P. Y., Martin, J. N., Daniel Kelly, J., Glidden, D. V., Deeks, S. G., & Henrich, T. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-09-27
- Volume
- 224
- Issue
- 11
- Pages
- 1839-1848
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W3206070584
- Cited by
- 320
- References
- 52
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.